drugset / Trial / NCT01224262
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
Phase 1/2
Completed
152 enrolled
Liquidia Technologies, Inc.
Accelovance · collabChildren's Hospital Medical Center, Cincinnati · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LIQ001 | Unknown | 0.45 mg | — |
| Subject | LIQ001 | Unknown | 1.8 mg | — |
| Background | Influenza Virus Vaccine | Vaccine | — | — |